ReviewCell and tissue banking2026
Smart and stimuli-responsive hydrogels for controlled exosome delivery in bone tissue engineering: from passive carriers to intelligent therapeutic platforms.
Review in Cell and tissue banking, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone regeneration follows a tightly coordinated biological sequence in which inflammatory resolution, vascular formation, and matrix mineralization occur within distinct temporal windows. However, most current exosome delivery strategies primarily extend retention rather than synchronize therapeutic signaling with these dynamic healing stages. This mismatch between release kinetics and biological demand may limit the regenerative potential of extracellular vesicle therapies. This review proposes a biology-driven framework that reinterprets stimuli-responsive hydrogel systems according to their capacity to coordinate stage-specific exosome delivery throughout bone healing. Recent literature on hydrogel-based exosome delivery systems was critically analyzed and interpreted according to their ability to regulate therapeutic timing rather than stimulus type, encompassing endogenous-responsive, externally triggered, and hybrid platforms. Particular emphasis was placed on release kinetics, osteoimmunomodulation, angiogenic coupling, translational feasibility, and emerging adaptive delivery concepts. Current preclinical evidence suggests that stimuli-responsive hydrogels capable of synchronizing exosome release with successive stages of bone healing may improve inflammatory regulation, vascularization, and osteogenesis compared with passive delivery systems. However, these biological effects remain dependent on hydrogel formulation, exosome source, and experimental model. Multi-responsive and adaptive platforms appear particularly promising for achieving sequential therapeutic signaling, although most remain at the proof-of-concept or preclinical stage. Rather than functioning solely as sustained-release carriers, future exosome delivery systems are likely to evolve toward adaptive therapeutic platforms capable of integrating microenvironment sensing with programmable release behavior. The biology-driven framework proposed in this review provides a complementary perspective for the rational design of next-generation regenerative biomaterials while highlighting the key experimental and translational challenges that must be addressed before clinical implementation.
Indexed as
Identifiers
42479219What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.